Biosig Technologies (NASDAQ:STEX) Major Shareholder Acquires $317,000.00 in Stock

Biosig Technologies, Inc. (NASDAQ:STEX) major shareholder Frank Giustra purchased 100,000 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were bought at an average price of $3.17 per share, with a total value of $317,000.00. Following the purchase, the insider directly owned 1,278,205 shares in the company, valued at approximately $4,051,909.85. The trade was a 8.49% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Frank Giustra also recently made the following trade(s):

• On Friday, January 23rd, Frank Giustra acquired 1,000,000 shares of Biosig Technologies stock. The stock was bought at an average cost of $3.00 per share, with a total value of $3,000,000.00.

Biosig Technologies Trading Down 5.7%

NASDAQ:STEX traded down $0.19 during trading hours on Wednesday, hitting $3.13. 5,436,828 shares of the company traded hands, compared to its average volume of 1,914,612. The stock has a market cap of $499.56 million, a PE ratio of -2.32 and a beta of 1.50. Biosig Technologies, Inc. has a one year low of $0.40 and a one year high of $14.11.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings assumed coverage on shares of Biosig Technologies in a research note on Friday, January 23rd. They issued a “sell (d-)” rating for the company. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.